Skip to main content

Financial News

  • Walgreens increases regular quarterly dividend

    DEERFIELD, Ill.  — Walgreens Boots Alliance on Thursday announced that its board of directors has declared a regular quarterly dividend of 37.5 cents per share, an increase of 4.2% over the year-ago period.

    Walgreens Boots Alliance and its predecessor company, Walgreens, have paid a dividend in 337 straight quarters (more than 84 years) and have raised the dividend for 41 consecutive years.

    The dividend is payable March 10, 2017 to stockholders of record as of Feb. 15, 2017.

     

  • Retail execs optimistic about 2017 in survey

    Retailers executives are bullish on 2017.
     
    That’s according to a survey from TD Bank, which polled 173 retail executives at the National Retail Federation’s annual Big Show in New York City. Seventy-four percent of the retailers said they believe sales will increase in the next 12 months. What’s more, 81% of the retailers reported that they met or exceeded their revenue goals in 2016.
     
    In other key findings:

  • Federal judge blocks Aetna, Humana merger, citing competition concerns

    WASHINGTON — The proposed $37 billion merger between Aetna and Humana hit a roadblock Monday, when U.S. District Court Judge John Bates issued his ruling in a lawsuit between the companies and the federal government. The Dept. of Justice sued on behalf of 264 counties in 21 states where it said a merger would limit competition unlawfully in the Medicare Advantage markets and 17 counties in three states where it said public exchange competition would be limited.
     

  • J&J exploring strategic options for LifeScan unit

    NEW BRUNSWICK, N.J.  — Johnson and Johnson on Tuesday announced it will be evaluating "potential strategic options" for its LifeScan diabetes business, as well as other J&J diabetes banners including Animas Corp. and Calibra Medical.

    The news was announced in conjunction with the company's fourth quarter earnings call, and is part of the company's ongoing portfolio management.

  • Analyst: Walgreens' Rite Aid deal still on point

    NEW YORK — Challenging "vague" reports suggesting the Walgreens deal to acquire Rite Aid may be in jeopardy, Deutsche Bank on Friday issued a research note outlining the number of options Walgreens still has at its disposal leading up to the Jan. 27 deadline.

  • Teva completes sale of U.K., Ireland Actavis business to Intas’s Accord Healthcare

    JERUSALEM and AHMEDABAD, India — The sale of Teva’s Actavis U.K. and Actavis Ireland to Intas Pharmaceuticals through its subsidiary Accord Healthcare for £603 million, Intas announced Tuesday. The transaction is part of the European Commission’s antitrust divestiture requirements surrounding Teva’s acquisition of Allergan’s generics business. 
     

  • Takeda to acquire Ariad Pharmaceuticals

    CAMBRIDGE, Mass. And OSAKA, Japan — Takeda on Monday announced its plan to acquire Ariad Pharmaceuticals for approximately $5.2 billion. The boards of both companies unanimously approved the transaction, and the companies expect it to close by the end of February. 
     

  • Jean Coutu Group sales up 1.9% despite generic pressures

    VARENNES, Québec  — The Jean Coutu Group on Friday posted a 1.9% increase in revenues to $576.8 million for the quarter ended Nov. 26.

X
This ad will auto-close in 10 seconds